Clinical trials: Dose Finding Study
Solid Tumors
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
This study is open to adults with advanced solid tumours. People with solid tumours for whom previous treatment was not successful or no treatment exists can take part.
- Trial name
- NCT05839600
- Testing
- BI 1821736
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Triple Negative Breast Cancer
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.
- Trial name
- NCT02003092
- Testing
- RX-5902
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Migraine
A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)
The purpose of this study is to investigate the efficacy and safety of an MK 0974 for migraine headache and to identify an appropriate dose range for further study.
- Trial name
- NCT00246337
- Testing
- MK0974, Rizatriptan
- Volunteers
- 420 people
- Sponsor
- Merck Sharp & Dohme LLC
Ocular Hypertension, Open Angle Glaucoma
Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma
The aim of this dose-finding clinical trial is to evaluate the systemic tolerability, local tolerability and intraocular pressure lowering effect of three different doses of SYL040012 in subjects with ocular hypertension or…
- Trial name
- NCT01739244
- Testing
- SYL040012
- Where
- 11 sites in Estonia, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- Sylentis, S.A.
Hypertrophy of Masseter Muscle
Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy
This study design is A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine the Safety and Efficacy of Meditoxin® in Subjects in Benign Masseteric Hypertrophy.
- Trial name
- NCT02292472
- Testing
- Botulinum Toxin Type A
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Medy-Tox
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Study CC-90002-AML-001 is an open-label, Phase 1 dose escalation (Part A) and expansion (Part B), clinical study of CC-90002, administered by intravenous (IV) infusion, in subjects with relapsed and/or primary refractory AML and…
- Trial name
- NCT02641002
- Testing
- CC-90002
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Celgene
Advanced Solid Tumor Cancer
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer
Phase Ib study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of HC010 in combination with chemotherapy regimens in patients with advanced lung cancer and determine the recommended dose for…
- Trial name
- NCT07381829
- Testing
- HC010, Paclitaxel (Chemotherapy), Pemetrexed
- Where
- China
- Volunteers
- 328 people
- Sponsor
- HC Biopharma Inc.
Pediatric Growth Hormone Deficiency
A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)
This study comprises two phases: Phase Ib and Phase II. Phase Ib is a multicenter, randomized, open-label, active-controlled, single-dose, dose-escalation to assess safety, tolerability, PK/PD profile, and immunogenicity of…
- Trial name
- NCT07450001
- Testing
- GenSci134 Injection, Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Constipation
Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)
The primary objective of the study was to evaluate the proportion of subjects with a bowel movement (BM) without straining or without hard and/or lumpy stool within the first 24 h of treatment for subjects taking 1 of 3 single…
- Trial name
- NCT01212445
- Testing
- PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)
- Where
- Ireland
- Volunteers
- 154 people
- Sponsor
- Bayer
Advanced Solid Tumors
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
This study has two parts: Part 1 and Part 2. The purpose of this study in Part 1, Dose Escalation Part is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of Debio 0123 as monotherapy with…
- Trial name
- NCT05109975
- Testing
- Debio 0123
- Where
- 15 sites in United States, Spain and 1 more
- Volunteers
- 93 people
- Sponsor
- Debiopharm International SA
Healthy Participants, Sarbecovirus
A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.
The purpose of this research study is to evaluate the safety of and the body's immune response to single and multiple vaccinations in healthy men and women. We want to find out what effects GBP511 has on you and your health.
- Trial name
- NCT07280858
- Testing
- Test Drug 1-1 (GBP511 low dose), Test Drug 1-2 (GBP511 mid dose), Test Drug 1-3 (GBP511 high dose)
- Where
- 3 sites in Australia
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
Functional Dyspepsia
A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
This is a multicenter, randomized, double-blind, placebo-controlled dose-finding phase 2 trial to evaluate the efficacy and safety of YH12852 in patients with functional dyspepsia.
- Trial name
- NCT02567578
- Testing
- YH12852 0.1 mg, YH12852 0.25 mg, YH12852 0.5 mg
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Yuhan Corporation
Labor, Obstetric
Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest
The study will be designed as a double-blind, placebo-controlled, parallel-group, dose-finding study with one group treated with placebo and three groups treated with tafoxiparin in three different infusion concentration levels…
- Trial name
- NCT03001193
- Testing
- DF 01, Oxytocin
- Where
- 12 sites in Denmark, Finland and 1 more
- Volunteers
- 361 people, healthy volunteers welcome
- Sponsor
- Dilafor AB
Pulmonary Disease, Chronic Obstructive
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This study will assess the safety and efficacy of 5 doses GW642444 in subjects with Chonic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT00606684
- Testing
- GW642444 6.25, GW642444 3mcg, GW642444 12.5mcg
- Where
- 99 sites in United States, Argentina and 12 more
- Volunteers
- 602 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test
The study has a randomized, double-blind, placebo-controlled, double dummy and eight-way cross-over design. Males with T2DM on a stable metformin monotherapy will be screened for participation in the study.
- Trial name
- DXM2 (NCT01936025)
- Testing
- Dextromethorphan, Sitagliptin
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Prostate Cancer
A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
This Phase Ib dose escalation study is designed to characterize the safety, tolerability and preliminary efficacy of i.v. panobinostat (LBH589) in combination with docetaxel and prednisone in the 1st line treatment of patients…
- Trial name
- NCT00663832
- Testing
- LBH589 (i.v. panobinostat)
- Where
- 9 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination…
- Trial name
- AMARONE (NCT05919693)
- Testing
- Remigromig
- Where
- 32 sites in United States, Argentina and 2 more
- Volunteers
- 33 people
- Sponsor
- EyeBiotech Ltd.
Allergic Rhinitis, Allergic Rhinoconjunctivitis
SUBLIVAC FIX Phleum Pratense DT/DRF
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Phleum pratense based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Phleum pratense…
- Trial name
- NCT01682070
- Testing
- SUBLIVAC FIX phleum prat.
- Where
- 23 sites in Germany, Poland
- Volunteers
- 266 people
- Sponsor
- HAL Allergy
Renal Cell Carcinoma
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Despite substantial improvements of patients outcome in advanced RCC, durable and complete response is uncommon. The majority of patients eventually develop resistance and exhibit disease progression.
- Trial name
- NCT02133742
- Testing
- Axitinib, MK-3475
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Pfizer
Pediatric Tumor of CNS, Pediatric Tumor of Brain
A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
This is an open label, Phase 1b safety, dose-finding, brain tumor delivery, and pharmacokinetics study of intranasal NEO100 in patients with pediatric-type diffuse high grade gliomas.
- Conditions
- Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem
- Trial name
- NCT06357377
- Testing
- NEO100
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Neonc Technologies, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.